Contact Us
Contact Us
Contact Us

Technology

Platform Technology Overview 

Scientific Excellence with Proven Leadership Advisory board comprising India’s most decorated scientists in nanotechnology and translational oncology; management team with successful healthcare exits

Proprietary Technology Platform Patent-protected nanoformulation technology demonstrating superior biosafety and targeting specificity compared to existing nanoparticle-mediated therapies 

Mechanism of Action & PharmacodynamicsActive Targeting with Controlled Therapeutic Activation

  • Phase 1: Receptor-Mediated Cellular Targeting:
    Surface-conjugated cyclic RGD peptides exhibit high-affinity binding to αvβ3 and αvβ5 integrins, which are overexpressed on tumor neovasculature and various cancer cell phenotypes. This active targeting mechanism achieves 5-10x higher tumor accumulation compared to passive EPR (Enhanced Permeability and Retention)-dependent delivery.
  • Phase 2: Photothermal Activation:
    Upon Near-Infrared (NIR) laser irradiation (typically 808 nm), gold nanoparticles demonstrate localized surface plasmon resonance, converting photonic energy to thermal energy with high efficiency. This generates controlled hyperthermia (42-47°C) at tumor sites, inducing apoptotic and necrotic pathways.
  • Phase 3: Triggered Drug Release:
    Thermosensitive liposomal bilayers undergo phase transition at hyperthermic temperatures, enabling on-demand cargo release precisely at disease sites. This spatiotemporal control minimizes offtarget drug exposure while maximizing local therapeutic concentrations.
  • Therapeutic Outcomes:
    • Tumor-specific thermal ablation.
    • Localized controlled drug release.
    • Minimal systemic drug exposure.
    • Reduced off-target toxicity.
    • Enhanced therapeutic index (>10x improvement in preclinical models).

Technology Advantages & Comparative PerformanceSuperior Design Addressing Critical Limitations Biodegradable  

  • Biodegradable Architecture:
    • Liposomal components metabolized through endogenous phospholipase pathways.
    • Gold nanoparticles sized for efficient renal clearance (<6 nm).
    • No accumulation in reticuloendothelial system.
    • Demonstrated safety profile with minimal hepatotoxicity or nephrotoxicity.
  • Gold Nanoparticle Advantages:
    • Strong NIR absorption for photothermal conversion.
    • Surface chemistry enabling facile bioconjugation.
    • Excellent biocompatibility (FDA precedent in approved diagnostics).
    • Dual functionality: therapy and imaging (theranostic potential).
    • Quantum confinement effects at optimal size range.
  • RGD-Mediated Active Targeting:
    • Receptor-mediated endocytosis for efficient cellular uptake.
    • Surface chemistry enabling facile bioconjugation5-10x enhanced tumor accumulation vs. passive targeting.
    • Specificity for integrin-overexpressing tumor phenotypes.
    • Significantly improved therapeutic index.
    • Reduced required dosage and treatment frequency.

Technology Architecture Design

Imagine a Bus with a driver with navigational programmed tools and passenger seats. The driver follows the navigational destinations and passengers demounts at specific destination.

Our system is like a Nano Bus made up of bio available & bio degradable material with Driver – peptides complex proteins programmed for specific diseased area / destination. Passengers are Pure Formulations,  Actives or moiety, molecules programmed to demount at specific area.  

Currently our application is clinically proven and some also manufactured at GMP scale for:

  • Skin care/ Personal care (human / vet) 
  • Wound care/ Healing (human / vet) 
  • Oncology / Cancer care
Explore More
/ Engineering the Next Era of Technology. / Small Science, Big Impact. / Nano Solutions for a Sustainable World. 
/ Engineering the Next Era of Technology. / Small Science, Big Impact. / Nano Solutions for a Sustainable World. 
/ Where Science Meets Infinite Possibilities. / Transforming Ideas into Impactful Innovations. 
/ Where Science Meets Infinite Possibilities. / Transforming Ideas into Impactful Innovations. 

Overcoming First-Generation Nanomedicine LimitationsSecond-Generation
Nanocarrier Design

  • Limitations of Current Plasmonic Nanostructures:
    • Gold nanorods, nanoshells: Non-biodegradable; chronic accumulation concerns.
    • CTAB-stabilized systems: Cytotoxicity from cationic surfactants.
    • Large particle diameters (>100 nm): Poor tumor penetration, RES accumulation.
    • Regulatory pathway challenges for non-degradable metallic systems.
  • Limitations of Passive Nanocarrier Systems:
    • EPR effect variability across tumor types and patients.
    • Insufficient tumor accumulation (<5% injected dose typically).
    • No cellular-level specificity.
    • Heterogeneous intratumoral distribution.
  • Limitations of Antibody-Drug Conjugates (ADCs):
    • High manufacturing complexity and cost ($10,000-100,000/gram).
    • Large molecular weight limiting tissue penetration.
    • Immunogenicity concerns with repeated dosing.
    • Batch-to-batch variability in conjugation chemistry.
  • AuLipos Solution:
    Our integrated platform combines the advantages of multiple approaches while eliminating key limitations: biodegradable carrier, active targeting specificity, cost-effective manufacturing (<$1,000/gram projected at scale), and straightforward regulatory pathway through established liposomal and gold nanoparticle precedents.
Explore more

Therapeutic Applications & Platform VersatilityMulti-Modal Applications Across Therapeutic Areas

Oncology - Targeted Photothermal Therapy
  • Solid tumor ablation with minimal invasiveness
    Anti-metastatic.
  • applications through neovasculature targeting
  • Combination chemo-PTT regimens.
  • Potential across multiple cancer types (oral, breast, colorectal).
Theranostic Applications
  • Simultaneous diagnostic imaging and therapeutic delivery.
  • MRI contrast agent co-loading capability.
  • Fluorescence imaging for surgical guidance.
  • Real-time treatment monitoring.
Enhanced Chemotherapy Delivery
  • Controlled-release kinetics optimizing drug exposure.
  • Reduced systemic toxicity enabling dose intensification.
  • Overcoming multidrug resistance mechanisms.
  • Improved pharmacokinetic profiles.
Inflammatory Disease Applications
  • Wound healing through targeted anti-inflammatory delivery.
  • Dermatological conditions with dysregulated integrin expression.
  • Autoimmune disease targeting of activated immune cells.

nanotechnologyFrom Lab to Industry

What sets Infinano apart is our ability to bridge research and commercialization. Many nanotechnology discoveries remain confined to academic studies — but we focus on scalability and real-world integration.

Proprietary Processes
We develop unique synthesis and functionalization methods for nanomaterials.
Industrial Compatibility
Our innovations are engineered to integrate seamlessly into existing production systems.
Pilot to Scale
From proof-of-concept to mass manufacturing, we ensure technologies are market-ready.

Collaborating to Build a Smarter Future

Initiate Discussion